Phenoconversion in Pure Autonomic Failure
JAMA Neurology · 2026
DOI: 10.1001/jamaneurol.2026.0989 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift JAMA Neurology, 2026. Verfasst von Sasivimol Virameteekul und 8 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom. Hauptthemen laut MEDLINE: Pure Autonomic Failure, Multiple System Atrophy, Parkinson Disease, Lewy Body Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Pure autonomic failure (PAF) can be the prodromal presentation of Parkinson disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA), although phenoconversion rates and predictors have not been systematically reported.
Objective
To estimate phenoconversion rates for MSA, PD, and DLB separately and grouped as central α-synucleinopathies and identify clinical predictors of phenoconversion in patients with PAF. Data Sources PubMed and Embase databases from inception to June 2025. Study Selection Longitudinal studies including patients with confirmed PAF reporting data on incidence and/or predictors of phenoconversion. Data Extraction and Synthesis Studies were screened and data extracted by 2 independent investigators according to PRISMA guidelines. A meta-analysis was performed using generic inverse-variance random-effects models. Main Outcomes and Measures PD, DLB, MSA, and central α-synucleinopathy phenoconversion incidence rates as per 100 person-years were the main outcomes. Incidence rates were log transformed and pooled using a random-effects meta-analysis. Clinical predictors of phenoconversion were reported as secondary outcomes. Prediction intervals and meta-regression explored study-level moderators.
Results
A total of 9 studies comprising 900 individuals with PAF (mean [SD] age at onset, 63.1 [4.3] years; 63.8% male) were included. During the mean (SD) 6.4 (2.0) years of follow-up, 270 of 900 individuals with PAF (30%) experienced phenoconversion to a central α-synucleinopathy (12% to MSA, 11% to DLB, 7% to PD) with a pooled incidence rate of 5.09 per 100 person-years (95% CI, 3.79-6.85; approximately 5% per year). Phenoconversion rates for MSA (pooled incidence rate, 1.96; 95% CI, 1.29-2.99) were highest in the first years of follow-up, whereas Lewy body disorders showed more constant phenoconversion rates (DLB pooled incidence rate, 1.56; 95% CI, 0.94-2.61; PD pooled incidence rate, 1.35; 95% CI, 0.75-2.41). Hyposmia was the only predictor with diagnostic value to distinguish between those with phenoconversion to PD and DLB (hyposmia pooled risk ratio, 1.88; 95% CI, 1.26-2.97) and MSA, although rapid eye movement sleep behavior disorder (RBD) and subtle motor signs were consistent predictors of phenoconversion to any central α-synucleinopathy. Heterogeneity was partly explained by follow-up duration. Conclusions and Relevance Findings of this systematic review and meta-analysis suggest that PAF may be a prodromal presentation of PD, DLB, or MSA with phenoconversion incidence rates similar to those of RBD. A combination of clinical (RBD, subtle motor signs, hyposmia) and in-development biomarkers may help refine the phenoconversion trajectories of people with PAF providing an invaluable opportunity for early diagnosis and intervention.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Centre for Preventive Neurology, Wolfson Institute of Population Health, Queen Mary University of London, London, United Kingdom.
- Department of Biochemistry, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
- Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria.
- Department of Neurology, Azienda Sanitaria Universitaria Integrata del Trentino, Trento, Italy.
- Department of Neurology, Oslo University Hospital, Oslo, Norway.
- Neurology Department, Royal London Hospital, Barts Health NHS Trust, London, United Kingdom.
Zitieren
APA
Virameteekul, S., Bonini, I., Campese, N., Mahlknecht, P., Tan, M., Poewe, W., Noyce, A. J., Fanciulli, A., & de Pablo-Fernández, E. (2026). Phenoconversion in Pure Autonomic Failure. JAMA Neurology. https://doi.org/10.1001/jamaneurol.2026.0989
Vancouver
Virameteekul S, Bonini I, Campese N, Mahlknecht P, Tan M, Poewe W, et al. Phenoconversion in Pure Autonomic Failure. JAMA Neurology. 2026. doi:10.1001/jamaneurol.2026.0989
BibTeX
@article{Virameteekul2026,
author = {Virameteekul, Sasivimol and Bonini, Ilenia and Campese, Nicole and Mahlknecht, Philipp and Tan, Manuela and Poewe, Werner and Noyce, Alastair J and Fanciulli, Alessandra and de Pablo-Fernández, Eduardo},
title = {Phenoconversion in Pure Autonomic Failure},
journal = {JAMA Neurology},
year = {2026},
doi = {10.1001/jamaneurol.2026.0989}
}
EUVIMED